Tempus AI has expanded its precision medicine portfolio with the acquisition of Paige, a digital pathology firm holding nearly seven million digitized pathology slides from diverse populations across 45 countries. The deal, primarily stock-based, integrates Paige’s advanced AI applications, including the first FDA-cleared AI pathology tool, augmenting Tempus’ dataset and technical expertise. With Paige’s foundation model, Virchow, designed to accelerate cancer research and drug discovery, the acquisition accelerates Tempus’ ambition to build the largest oncology foundation model to date. CEO Eric Lefkofsky highlighted the strategic importance of this expanded capability to enhance diagnostic insights earlier in patient care.